Introduction
Gastric cancer is one of the most common digestive system malignancies in the world.1 According to statistics, gastric cancer ranks third in cancer-related deaths, with more than 1 million new cases worldwide each year.2 Due to the lack of specific symptoms, more than 80% of gastric cancer patients are diagnosed at an advanced stage. In recent years, with the development of immunotherapy, targeted therapy and neoadjuvant chemotherapy, the prognosis of gastric cancer patients has been greatly improved, but the five-year survival rate for patients with stage IV gastric cancer remains below 10%.3–5
There is no consensus among different countries on the indications for neoadjuvant chemotherapy. The National Cancer Comprehensive Network Guidelines recommend…